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A B S T R A C TObjectives: Central line associated bloodstream infections (CLABSIs)
impose a significant economic burden for patients admitted to the
intensive care unit for adults (AICU). The objectives of the study were
to evaluate the excess length of stay and extra costs attributable to
CLABSIs diagnosed in the AICU. Methods: Cases were selected as
patients admitted to AICU from 2006 through 2009, who developed a
CLABSI episode. These were matched (1:1) with appropriate controls.
Matching criteria were selected to exclude other factors that could
influence cost and care practices. The length of stay and resources
used between AICU admission and discharge and until hospital
discharge or death were measured. Incremental costs and lengths of
stay were calculated for each pair of patients. Results: Thirty cases
and 30 controls were included in the study. A CLABSI episode resultednt matter Copyright & 2012, International Society
r Inc.
.1016/j.vhri.2012.10.002
rest: The authors have indicated that they have n
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ondence to: Claudia Balbuena Dal Forno, Av. Albertin an additional 10.5 days in the AICU and 9.1 days after AICU
discharge, totaling an additional 19.6 days. The incremental cost
associated with a CLABSI episode was US $65,993 in the AICU and
US $23,893 after AICU discharge, totaling an incremental cost of US
$89,886. Conclusions: By avoiding CLABSI events, cost offsets would
be expected for payers with revenue losses to providers. An
approach of sharing the gains resulting from preventive measures
could be used to incentivize providers to maintain those invest-
ments, benefiting patients who will have a reduced risk of CLABSI
development.
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Central venous lines are used extensively in intensive care units
(ICUs) but may occasionally result in central line associated
bloodstream infections (CLABSIs). In the United States, about
48,600 CLABSIs occur in ICUs each year [1]. These infections
impose a significant economic burden, with additional estimated
costs ranging from US $4,000 to US $36,000 per episode [2–4].
Critically ill patients with primary bloodstream infections are
hospitalized for an average of 6.5 to 22 days longer than are
patients without bloodstream infection [2–4]. Data from Latin
America and other developing countries participating in the
International Nosocomial Infection Control Consortium show
that CLABSI rates in these countries are three to five times higher
than rates in the United States [5].
Preventing CLABSI may improve patient care while reducing
hospital stays, costs, and possibly also mortality. Central venous
line bundles are fairly simple to perform with reproducible
results. However, the implementation of these interventions
requires a considerable investment in resources and manpower.
Hospital Israelita Albert Einstein (HIAE) has implemented pre-
ventive measures in two phases, March 2005 to March 2007 phase1 and April 2007 to April 2009 phase 2. Considering the study
period we will report actions related to phase 2. Continuing the
quality improvement measures, we implemented the Institute
for Healthcare Improvement bundle (creation of a central cathe-
ter insertion cart; hand hygiene; maximal barrier precautions for
insertion; chlorhexidine skin antisepsis; optimal site selection,
with avoidance of the femoral vein for central venous access in
adult patients; daily review of line necessity with prompt removal
of unnecessary lines for all patients admitted to the ICU for
adults [AICU]). This bundle was monitored every day by AICU
nurses and doctors. The insertion process was interrupted at the
same time that performance monitoring was occurring at the
bedside if noncompliance with an element of the bundle was
detected. Prior to the start of phase 2, we delivered a brief
presentation to the AICU staff on CLABSI prevention, reviewed
the study protocol, and encouraged participation in our ‘‘central
line bundle – getting to zero’’ program. Monthly, we sent an e-
mail to the team with feedback on compliance with the bundle
and provided posters in the AICU with bar graphs displaying
compliance measures and the CLABSI rate. A group of physicians
was implemented to remove the unnecessary catheters every
day. Compliance with all process measures while inserting thefor Pharmacoeconomics and Outcomes Research (ISPOR).
o conflicts of interest with regard to the content of this article.
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were placed in the AICU [6]. In respect of the implantation costs, all
materials required for the bundle were already standardized in our
hospital and were already used in the insertion process, but not
organized in the bundle form. The jointly further measures were
just behavioral actions without the addition of direct costs. The
training time spent was already included in the preexisting
program of quality care in the AICU.
Between 2008 and 2010, the rate of CLABSI per 1000 catheter-
days was reduced from 5.7 to 1.5 events per 1000 catheter-days.
This reduction resulted in an estimated 85 avoided CLABSI events.
The lack of data on the economic burden of CLABSI in Brazil
motivated us to measure the impact of reduction in CLABSI,
evaluating the excess length of stay (LOS) both in the ICU and in
the hospital and the extra costs attributable to these infections [7].
The objectives of the study were to evaluate the excess LOS in
the AICU and in the hospital and extra costs attributable to
CLABSI diagnosed in the AICU in a single institutional setting.
This information will allow for discussion with leaderships and
provide objective data for decision making.* BSI = Bloodstream infection; CLABSI = Central line associated
bloodstream infection; AICU = adult intensive care unit. 
1,615  patients with hospital-
acquired infection between 
2006 and 2009 
370 patients with at least one 
episode of bloodstream 
infection (BSI) 
30 patients with CLABSI 
diagnosed in the AICU 
included in the analysis 
Exclusions: 
54 patients with more than one BSI 
episode 
234 patients with BSI diagnosed outside 
the AICU 
4 patients with BSI not associated to 
central line 
47 patients with more than 1 admission 
to AICU 
1 patient without hospital discharge 
documentation 
Fig. 1 – Patient selection. AICU, intensive care unit for
adults; BSI, bloodstream infection; CLABSI, central line
associated bloodstream infection.Methods
Setting
This study was conducted at HIAE, which is a tertiary care,
private hospital with 577 single-bed rooms, located in S ~ao Paulo,
Brazil. The AICU has 40 beds. The rooms are configured in seven
4-room and two 6-room suites or ‘‘pods.’’ The AICU has an open
staffing model and approximately 2800 patients are admitted
annually. The average LOS in the AICU is 3.96 days. The AICU
receives patients from all clinical specialties, including bone
marrow transplant and surgical specialties such as solid organ
transplant and bariatric surgery.
Study Design
The study was developed as a pair-wise matched (1:1) case-
control study.
Cases were identified through prospective active surveillance
conducted by HIAE Infection Control and Prevention Team by
using the Centers for Disease Control and Prevention definitions
for CLABSI [8]. Case patients were defined as those admitted to
medical-surgical AICU from January 1, 2006, through December 31,
2009, who had a CVC and who developed a CLABSI. We excluded
from the analysis patients with more than one admission to the
AICU, with more than one episode of bloodstream infection, or
episodes of hospital-acquired infection other than CLABSI.
There is a great concern in the literature about the methodol-
ogy used for cost analysis, because of the risk of biasing the
results by not choosing the appropriate controls. The matching
criteria used in the study were carefully chosen so as to exclude
other confounding factors that could influence cost and care
practices, such as the date of AICU admission.
Matching criteria were applied in the following order for the
selection of controls: no documented episode of CLABSI, use of
CVC, type of patient outcome (death or hospital discharge),
diagnosis on hospital discharge (International Statistical Classifica-
tion of Diseases, 10th Revision), Acute Physiology and Chronic
Health Evaluation II (APACHE II) category based on mortality risk
[9], LOS in the AICU of controls equivalent to time from AICU
admission until CLABSI diagnosis for cases (2 days), hepatic
disease (defined as the presence of cirrhosis, acute gastroin-
testinal bleeding, portal hypertension, hepatic failure, or liver
encephalopathy), dialysis-dependent renal failure, use of mechan-
ical ventilation, date of AICU admission (1 year), prior solid organtransplantation, age (5 years), gender, New York Heart Associa-
tion functional classification IV [10] in patients with heart disease,
diagnosis of metastatic cancer, and immunodeficiency (defined as
the use of chemotherapy, radiotherapy, or high-dose corticoster-
oids; diagnosis of leukemia, lymphoma, multiple myeloma, or
acquired immunodeficiency syndrome). Criteria were presented
in the priority order considered for matching and were defined to
account for characteristics that could influence costs, irrespective
of the occurrence of CLABSI [10].
The AICUmaintains a prospective collection of epidemiological,
clinical, laboratory, and outcomes data for all patients admitted to
AICU, generating a database from which controls were selected. A
linear mathematical model was used to maximize the matching
criteria in the priority sequence presented above.
Study Definitions
The LOS between AICU admission and AICU discharge or death
and between AICU admission and hospital discharge or death
were measured for cases and controls and the incremental
lengths of stay were calculated for each pair of patients.
In the Brazilian private health care system, costs associated
with CLABSI events usually impact third-party payers, mainly
private insurers, because fee for service is the predominant
reimbursement structure for providers. Therefore, the perspec-
tive of private health plans was chosen for this cost analysis.
All resource use was documented from the AICU admission
until hospital discharge. The resource use included hospital stay,
drugs, materials, exams, and procedures. Unit costs were defined
from the perspective of private payers (unit revenues from the
hospital perspective) and obtained from the HIAE billing system
to reflect the expected hospital revenue per item. All costing
information was adjusted to 2010 values, considering unit rev-
enues based on the latest hospital price table at the time of the
analysis. Costs were obtained in Reais and converted to US
dollars considering the exchange rate of R $1.87 per US dollar.
The number of units used by each patient was multiplied by its
unit cost to estimate average total costs per patient for two
periods: between AICU admission and AICU discharge or death
and between AICU admission and hospital discharge or death.
Incremental costs were calculated for each pair of patients.
Statistical Analysis
The analyses were performed by using KNIME software [11].
Differences between matched pairs were used as the primary
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incremental costs. To test for mean differences of continuous
variables among matched pairs, the analyses of variance test
was used for normally distributed variables according to the
Kolmogorov-Smirnov test and with homogeneity in variances
according to the Levene test. For nonnormally distributed variables,
the nonparametric Mann-Whitney test was used. Analyses result-
ing in a P value below 0.05 were considered statistically significant.Table 1 – Characteristics of patients included in the analysis.
Characteristics
N
Age
% Male
APACHE (average)
APACHE category (%)
3
4
5
6
7
Comorbidities (%)
Hepatic disease
On dialysis end-stage renal disease
Cardiovascular disease
Metastasis
Immunodeficiency
Solid organ transplantation
% Use CVC
% Use of mechanical ventilation
Length of stay prior to CLABSI or AICU discharge
Year of admission to AICU (%)
2005
2006
2007
2008
2009
% Death
Hospital discharge diagnosis (ICD-10) (%)
Cerebrovascular disease
Demyelinating diseases of the central nervous system
Diseases of the esophagus, stomach, and duodenum
Liver disease
Peritoneum disease
Viral hepatitis
Influenza [flu] and pneumonia
Malignant neoplasms
Other bacterial diseases
Other respiratory diseases
Other forms of heart disease
Other disorders of the nervous system
Disorders of gallbladder, bile ducts, and pancreas
Head injuries
Ischemic heart disease
Hip and thigh injuries
Injuries to the elbow and forearm
Noninfectious enteritis and colitis
Mycoses
Benign neoplasms
AICU, intensive care unit for adults; APACHE, Acute Physiology and Chro
infection; CVC, central venous catheter; ICD-10, International Statistical ClResults
During the study period, 1615 patients were diagnosed
with a hospital-acquired infection. Among those, 370 patients
had at least one bloodstream infection. Thirty patients were
included in the final analysis, and exclusions are detailed in
Figure 1.Cases Controls P
30 30 –
58 70 0.012
73 63 0.405
17.5 19.1 0.492
17 13 0.693
60 57
20 17
3 10
0 3
20 17 0.739
0 0 –
0 0 –
0 0 –
27 13 0.197
10 10 –
100 100 –
97 100 0.313
16.6 16.3 0.934
0 13 0.192
53 40
33 23
10 20
3 3
53 53 –
3 7 0.864
3 0
0 3
13 17
3 3
7 7
10 17
17 20
7 7
3 0
3 3
3 3
3 3
7 3
3 3
3 0
0 3
3 0
3 0
3 0
nic Health Evaluation II; CLABSI, central line associated bloodstream
assification of Diseases, 10th Revision.
Table 2 – Microoganisms involved in 30 episodes of CLABSI.
Gram-positive bacteria n Gram-negative bacteria n
Staphylococcus aureus 3 Acinetobacter baumannii 4
Staphylococcus epidermidis 4 Klebsiella pneumoniae 3
Staphylococcus haemolyticus 2 Escherichia coli 2
Staphylococcus capitis 1 Pseudomonas aeruginosa 2
Staphylococcus simulans 1 Enterobacter cloacae 1
Staphylococcus hominis 1 Proteus mirabilis 1
Others
Candida albicans 1
Candida tropicalis 1
Candida krusei 1
Trichosporon asahii 1
AICU, intensive care unit for adults. CLABSI, central line associated bloodstream infection.
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for the criteria previously listed were 100% for the use of CVC,
type of outcome, need for dialysis, prior solid organ transplanta-
tion, presence of cardiovascular disease, and metastatic cancer;
97% for the LOS in the AICU and need of mechanical ventilation;
90% for the presence of hepatic failure; 87% for diagnosis on
hospital discharge, date of admission to AICU, and presence of
immunodeficiency; 83% for APACHE category; 50% for gender;
and 17% for the age range.
Matching variables and baseline characteristics of matched
patients are summarized in Table 1, and the microorganisms
involved in the CLABSI episodes are described in Table 2. Only age
showed a statistically significant difference between cases and
controls.
In regard to the LOS, the average LOS for cases was higher than
for controls during AICU stay (27.8 days vs. 17.3 days; P ¼ 0.006) and
between AICU admission and hospital discharge or death (44.6 days
vs. 25.0 days; P ¼ 0.011). The incremental LOS associated with a
CLABSI episode was 10.5 days in the AICU and 9.1 days after AICU
discharge, totaling 19.6 days between AICU admission and hospital
discharge or death. Analyzing the results in relative terms, an
episode of CLABSI increased on average the AICU LOS in 61% of
total stay and the total hospitalization after AICU admission in 78%.
Concerning costs, the average cost for cases was higher than for
controls during AICU stay (US $209,564 vs. US $143,571; P ¼ 0.016)
and between AICU admission and hospital discharge or death (USTable 3 – Cost and length of stay results.
Outcomes Cases – average
(95% CI)
Controls – a
(95% C
Length of stay
AICU admission –
AICU discharge
27.8 d (22.8–33.5) 17.3 d (13.4–21.9
AICU admission –
hospital
discharge
44.6 d (31.6–62.1) 25.0 d (18.4–32.3
Hospitalization costs (US $)
AICU admission –
AICU discharge
209,564 (166,339–255,816) 143,571 (98,914–
AICU admission –
hospital
discharge
248,763 (195,848–311,113) 158,877 (114,091
* Exchange rate: US $1 ¼ R $1.87; 95% CI, 95% confidence interval. The CIs
through the nonparametric Mann-Whitney test for nonnormally distri$248,763 vs. US $158,877; P ¼ 0.016). The incremental cost asso-
ciated with a CLABSI episode was US $65,993 in the AICU and US
$23,893 after AICU discharge, totaling US $89,886 between AICU
admission and hospital discharge or death. Analyzing the results in
relative terms, an episode of CLABSI increased on average the AICU
cost by 46% and the total cost after AICU admission until hospital
discharge by 57%. Study results are summarized in Table 3.
Although no differences were found in terms of baseline
characteristics between cases and controls, patients with a
CLABSI episode were significantly more costly than controls.
Considering the estimated reduction of 85 CLABSI events
between 2008 and 2010 and the cost difference attributable per
event of US $89,886, the expected cost reduction for private
payers associated with the avoided CLABSI events would be US
$7.6 million. The detailed reductions and cost-savings are pre-
sented in Table 4.Discussion
CLABSIs are potentially preventable. Therefore, not only infection
control groups but also health care executives are focused on
reducing the incidence of these events [12].
Knowing the costs attributable to CLABSI and evaluating the
cost-effectiveness of quality and prevention measures is essen-
tial for the proper management of this issue. Many studies reportverage
I)
Absolute difference –
average (95% CI)
Relative
difference
(%)
P
) 10.5 d (7.1–15.0) 61 0.006
) 19.6 d (9.1–33.9) 78 0.011
196,268) 65,993 (24,621– 105,918) 46 0.016
–212,847) 89,886 (40,579–146,519) 57 0.016
were generated through boostrapping. The P values were calculated
buted variables.
Table 4 – Observed CLABSI reductions and estimated cost-savings.
Year 2007 2008 2009 2010 Total
CLABSI episodes 39 21 10 12
CVC days 6,816 6,920 7,498 7,750
Incidence/1,000 CVC days 5.7 3.0 1.3 1.5
Avoided CLABSI episodes 0 19 33 33 85
Cost-savings ($) 0 1,707,834 2,966,238 2,966,238 7,640,310
CLABSI, central line associated bloodstream infection; CVC, central venous catheter.
* The bundle implementation started in April 2007.
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increased use of resources and costs associated with patients
with CLABSI [14].
There is increasing concern among public and private man-
agers, as, for example, the federal government and private
insurers, about cost increases in health care. This concern is
related to health care as a whole, including the management of
adverse events and its consequences, hospitalization, incorpora-
tion of health care technologies, and management of chronic
patients. Knowing that the costs associated with CLABSI fall on
the payers, this study was developed from the perspective of
private payers in Brazil, operating on a predominantly fee-for-
service reimbursement system.
By including patients with a CLABSI event as cases and
matching them with appropriate controls without infection, we
demonstrated the immediate health benefits and cost savings
achieved in our institution.
Some other case-control studies used a similar approach for
matching cases and controls and tried to demonstrate the
incremental cost of a CLABSI episode. To define the cases and
controls, Pirson et al. [15] used the all patient refined diagnosis-
related groups for diagnosis matching. The extra cost related to a
CLABSI episode was h19,301 per patient. In the study by Pittet
et al. [2], the estimated cost was 33,268 per patient with a CLABSI
episode [2].
Between 2008 and 2010, the rate of CLABSI per 1000 catheter-
days at HIAE was reduced from 5.7 to 1.5 events per 1000
catheter-days. This reduction resulted in an estimated 85 avoided
CLABSI events. Considering the estimated additional cost per
event of US $89,886, the expected cost reduction for private
payers associated with the CLABSI events avoided would be US
$7.6 million.
The estimated cost associated with a CLABSI event at our
private hospital is higher than the values resulting from interna-
tional studies [2,13,16]. This may reflect differences in the
perspective adopted for the analysis. Differently from most of
the published studies, which considered hospital costs, we
applied hospital reimbursement values to account for costs from
the perspective of private payers. This is justified by the fact that
the increased costs associated with the CLABSI events are
actually reimbursed by private payers and therefore, avoiding
one event would result in cost offsets to payers. In Brazil, private
health care can either be obtained as a work benefit or be
purchased individually. In 2011, about 30% of the Brazilian
population was covered by private insurance and most private
plans (80%) were provided by commercial firms as a work benefit.
So, any health costs increment will impact directly or indirectly
on the patient and the consumer. In the international settings,
hospitalization reimbursement is usually fixed, irrespective of
the occurrence of CLABSI events, and the hospital perspective is
appropriate. In a fee-for service reimbursement system, devel-
oping the analysis from the perspective of the provider would
underestimate the financial benefit gained and would not reflect
the real magnitude of the achievements for private payers.Another factor that may influence cost variations among
studies is the fact that reimbursement fees for hospital stay,
exams, and procedures are negotiated on a hospital-by-hospital
basis with each private insurer.
Recognizing a number of limitations already described in the
literature about health economic studies [10,14], we sought to
minimize them as much as possible by increasing the rigor of the
matching criteria. One important variable included as a matching
criterion was the hospitalization-associated outcome (death or
hospital discharge), because this is a variable expected to influ-
ence costs independent of the presence of CLABSI [17].
The only criterion that showed a statistically significant
difference between cases and controls was age, as presented in
Table 1. This factor is included in the APACHE calculation;
therefore, patients with different ages might be considered
similar in terms of disease severity depending on the APACHE
category.
An additional analysis has been performed excluding the
three pairs of cases and controls who presented age differences
higher than 5 years and with APACHE categories also different.
The magnitude of the incremental costs between cases and
controls was maintained in relation to the base case.
An additional factor that presented an absolute difference of
14% between cases and controls was the presence of immuno-
deficiency, although without statistical significance. A new ana-
lysis was also performed excluding the four pairs of patients with
difference between cases and controls for the presence or
absence of immunodeficiency. The cost difference between cases
and controls was even higher in this new analysis in relation to
the base case.
The findings of this study corroborate the results of interna-
tional studies, concluding that CLABSI events are associated with
increased health care costs [2,13,14]. The current challenge in our
scenario is that although cost offsets are expected for payers
because of reductions in CLABSI incidence, the investment in
preventive and quality measures rests on providers.
An approach of sharing the gains resulting from preventive
measures could be used to incentivize providers to maintain or
even increase the investments in such programs, benefiting
patients, who will have a reduced risk of CLABSI development.
This could be achieved if hospitals with lower CLABSI rates would
be reimbursed with higher fees.Conclusions
This study aimed to evaluate the excess LOS in the AICU and in
the hospital and extra costs attributable to CLABSI diagnosed in
the AICU in a single institutional setting.’’ By using a pair-wise
matched case-control study, we estimated average additional
costs of US $65,993 in the AICU and US $89,886 until hospital
discharge. In terms of LOS, the impact was 10.5 days in the AICU
and 19.6 days until hospital discharge. This impact reflects
increased occupation rates for the hospital and increased costs
VA L U E I N H E A LT H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 1 3 6 – 1 4 1 141for third-party payers. By avoiding CLABSI events, cost offsets
would be expected for payers, with a potential increase in the
number of patients admitted to hospital because of released bed-
days.
Source of financial support: Funding for this project was
provided by Hospital Israelita Albert Einstein.
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